MWNA
ABUS icon

Marshall Wace North America’s Arbutus Biopharma ABUS Stock Holding History

Marshall Wace North America’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$955K Buy
+222,739
New +$742K ﹤0.01% 940
2021
Q2 		– Sell
-235,951
Closed -$786K – 1400
2021
Q1 		$786K Buy
+235,951
New +$910K ﹤0.01% 1099

Other funds holding ABUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Marshall Wace North America's ABUS Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Arbutus Biopharma (ABUS) in Q3 2021: 222,739 shares worth $955K. The stake represents ﹤0.01% of the portfolio and ranks #940 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in ABUS as recently as Q1 2021.

Marshall Wace North America first reported a position in ABUS in Q1 2021 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold ABUS as of Q3 2021.

  • Marshall Wace North America held 222,739 shares of Arbutus Biopharma worth $955K as of Q3 2021.
  • Arbutus Biopharma was a new Marshall Wace North America position in Q3 2021.
  • Arbutus Biopharma made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #940 holding.
  • Marshall Wace North America first reported a position in Arbutus Biopharma in Q1 2021 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.